#Germany #Frankfurt #CPHI Frankfurt #Taiwan TCM #Pandemic Innovation

Taiwan's TCM Pavilion Shines at CPHI Frankfurt 2025

In a remarkable showcase of innovation and collaboration, Taiwan's Traditional Chinese Medicine (TCM) Pavilion made its debut at CPHI Frankfurt 2025 from October 28-30. Organized by the Taiwan Institute of Economic Research and guided by the Department of Chinese Medicine and Pharmacy (DCMP) under Taiwan's Ministry of Health and Welfare, this pavilion marked a significant milestone in promoting traditional medicine on the global stage.

The event attracted international healthcare professionals and stakeholders, eager to engage in discussions on evidence-based TCM. The pavilion received notable attention, featuring Taiwan’s advancements in research and development, particularly in the realm of pharmaceuticals. Over three busy days, the pavilion welcomed 121 professional visitors and facilitated four business matchmaking sessions, connecting with five international companies and two investment organizations.

During this pivotal event, the pavilion had the honor to present on the CPHI Newsbeat Stage, a first for a Taiwanese exhibitor, further elevating Taiwan's global visibility. This session included a presentation on Taiwan's achievements in evidence-based TCM, followed by an interview with Raman Sehgal, host of the Molecule to Market podcast.

Key focus areas of the pavilion included NRICM101 and NRICM102, two TCM formulas developed by the National Research Institute of Chinese Medicine and approved by the MOHW. Supported by 11 peer-reviewed studies, these formulations exhibit significant antiviral and anti-inflammatory effects, making strides in reducing ICU admissions and mortality rates in COVID-19 patients, while also protecting against lung injuries and cognitive impairments post-infection.

Participating Taiwanese companies, including Chuang Song Zong, Li Kang Biotech, Timing Pharmaceutical, Taiwan Three Mast, and Grape King Bio, demonstrated the robustness of Taiwan's TCM ecosystem. Their contributions spanned areas such as clinical research, product innovation, GMP-certified manufacturing, as well as global OEM and ODM capabilities.

The success of the TCM Pavilion at CPHI Frankfurt serves as a testament to Taiwan's commitment to integrating traditional medicine into mainstream healthcare discourse. Dr. Yi-Chang Su, Director of the DCMP and NRICM, stated, "Our presence here underlines our dedication to delivering proven traditional medicine into the global healthcare dialogue." He expressed eagerness to leverage this momentum to enhance TCM cooperation and innovation internationally.

Furthermore, meetings between Mr. Mei-Shun Lo, the Director General of the Taipei Representative Office in Germany, and Bertram Roth, Vice President of FrankfurtRheinMain GmbH, emphasized the support for Taiwan’s pioneering TCM initiatives. Both leaders acknowledged the immense potential for Taiwan's TCM industry within the German market, envisioning fruitful cooperation with European partners.

As the world gradually recovers from the pandemic, the recognition and appreciation of Traditional Chinese Medicine continue to grow, and Taiwan is poised to play a pivotal role in this global conversation. With a commitment to scientific validation and collaboration, Taiwan's TCM Pavilion not only shone at CPHI Frankfurt 2025 but also laid the groundwork for future international partnerships in holistic health and wellness practices.